Testing Remibrutinib for papulopustular rosacea
Part of Skin clinical trials.
This study tests an experimental drug called remibrutinib (taken as a pill) to see if it can safely reduce the redness and bumps caused by papulopustular rosacea. It is for people with moderate to severe symptoms who have not had success with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have a confirmed diagnosis of papulopustular rosacea.
- Your rosacea is moderate to severe, with at least 15 inflamed bumps on your face (but not more than 2 cystic bumps).
- You agree to stop using certain antibiotics, other oral medications, and creams for rosacea starting 30 days before the study and during the study period.
- You have not taken remibrutinib or a similar BTK-inhibitor drug within the last 4 months.
- You do not have other active skin conditions on your face (like acne, seborrheic dermatitis, or perioral dermatitis) that could interfere with study results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called remibrutinib to see if it can reduce severe itching that has no clear cause. It aims to help people whose daily itching is very intense and not relieved by standard creams.
This study tests a new oral medication, remibrutinib, in adults with moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful lumps and tunnels. The goal is to see how the drug affects the skin tissue and to gather information for future treatments.
This study tests an investigational medicine (remibrutinib) for people with severe itching that has no known cause. It may help reduce the itch when moisturizers haven't worked.
This trial tests an experimental drug called Remibrutinib for people with chronic hives (urticaria) that are not well controlled with standard antihistamines. The goal is to see if the drug reduces symptoms like itching and wheals.
This study tests an investigational drug called remibrutinib to see if it can reduce allergic reactions to peanuts, milk, or eggs. It is for people aged 12 to 65 who have been diagnosed with a food allergy and are willing to participate in food challenges.
This study follows people with chronic spontaneous urticaria (long-lasting hives with no clear cause) who are starting a new medicine called remibrutinib or dupilumab. It aims to see how well these treatments work in everyday life.
Hear when a new Papulopustular Rosacea trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.